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ABSTRACT
Arming oncolytic adenoviruses with therapeutic
transgenes is a well-established strategy for multi-
modal tumour attack. However, this strategy some-
times leads to unexpected attenuated viral replica-
tion and a loss of oncolytic effects, preventing these
viruses from reaching the clinic. Previous work has
shown that altering codon usage in viral genes can
hamper viral fitness. Here, we have analysed how
transgene codon usage impacts viral replication and
oncolytic activity. We observe that, although trans-
genes with optimized codons show high expression
levels at the first round of infection, they impair vi-
ral fitness and are therefore not expressed in a sus-
tained manner. Conversely, transgenes encoded by
suboptimal codons do not compromise viral repli-
cation and are thus stably expressed over time, al-
lowing a greater oncolytic activity both in vitro and
in vivo. Altogether, our work shows that fine-tuning
codon usage leads to a concerted optimization of
transgene expression and viral replication paving the
way for the rational design of more efficacious on-
colytic therapies.
INTRODUCTION
Cancer is the second leading cause of death globally, ac-
counting for over 9 million deaths per year (https://www.
who.int/health-topics/cancer). The standard of care for tu-
mours still includes, in most cases, chemotherapies in com-
bination with surgery and radiation. For many patients,
these therapeutic strategies are associated with important
side effects and, unfortunately, are not always effective. An
alternative treatment, able to selectively self-amplify the
therapeutic effect in the tumour while not affecting healthy
tissues, represents an attractive clinical approach.
Lytic viruses replicate and expand killing the infected
cells. These properties of self-amplification and cell-lysis
make them, theoretically, ideal for antitumour therapies.
Nevertheless, for many viruses, their replication has not
evolved to target tumours, so their selectivity and efficacy
need to be rationally engineered. Oncolytic virotherapy is
a therapeutic approach consisting in the use of genetically
modified lytic viruses, engineered to replicate in cancer cells
in order to selectively kill them. Adenoviruses constitute an
attractive option as oncolytic viruses, as their replication cy-
cle is well known and they have potent lytic activity, can be
produced at high titres and are easily genetically modified.
In the past 20 years, multiple preclinical and clinical trials
have used these viruses as therapeutic agents in the treat-
ment of different tumours (1–6). Despite the encouraging
results in terms of safety, the efficacy of adenoviral treat-
ments still needs to be improved in order to increase the
clinical usefulness of this strategy (7).
Arming oncolytic adenoviruses (OAds) with therapeutic
transgenes is an attractive approach to increase their effi-
cacy. OAds are a highly versatile therapeutic platform that
allows oncoselective expression of a wide range of thera-
peutic molecules such as cytokines (8), extracellular ma-
trix modulators (6,9), immune checkpoint blockades (IBCs)
(10), bi-specific T-cell engagers (BiTEs) (11) or prodrug
converting enzymes (12), allowing a multimodal tumour
attack, from direct cell lysis to tumour microenvironment
modulation. Moreover, expressing therapeutic molecules
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through OAds provides the unique opportunity to attain
targeting tumours using therapeutic agents with unaccept-
able systemic toxicity profiles (13,14).
A standard strategy to maximize protein production in
gene therapy is the adaptation of the transgene codon us-
age to match that of the host cells. Although this could be an
intuitive strategy to maximize the expression of therapeutic
genes in OAds, previous results have shown that adenoviral
replication is tightly regulated through a balanced codon us-
age. In this way, viral genes avoid intergenic competition to
adequately exploit translational resources for efficient repli-
cation (15). This fact appears to be particularly important
at a late phase of infection, when viral genes become highly
expressed using the same finite pool of available cellular re-
sources (16).
In this work, we have assessed how this codon balance
can be affected by transgene expression, thus impacting
OAds’ therapeutic efficacy. This has been prompted by the
observation that the codon usage of late expressed thera-
peutic genes in OAds currently in the clinic is in fact sub-
optimal when compared to host codon usage. The system-
atic study of the codon usage of therapeutic transgenes pre-
sented in this work shows how transgene codon usage has
not only significant cis effects but also trans effects on other
viral proteins. We provide evidence on the importance of
studying armed OAds as a holistic system rather than con-
sidering the virus and its transgenes as separate elements.
We highlight the importance of developing codon usage
models to reduce transgene–viral intergenic competition,
thus not only maximizing transgene expression but also en-
suring adequate OAd replication. In this way, concerted
optimization of transgene expression and viral replication




Cell lines PANC-1 and MIA PaCa-2 (human pancreatic
carcinoma), A549 (human lung carcinoma), Jurkat (T-
cell leukaemia) and HEK293 (embryonic kidney) were ob-
tained from the American Type Culture Collection (ATCC,
Manasas, VA); human pancreatic adenocarcinoma cell
line NP18 was established and kindly provided by Dr
Gabriel Capellà (ICO-IDIBELL, Barcelona, Spain). All
cell lines were maintained in Dulbecco’s modified Ea-
gle’s medium (Gibco-BRL) supplemented with 10% foetal
bovine serum, penicillin (100 g/ml) and streptomycin (100
g/ml) (Gibco-BRL), and maintained in a humidified at-
mosphere of 5% CO2 at 37◦C except Jurkat cells that were
maintained in RPMI-1640 medium.
Expression plasmid generation and transfection
EGFP and LGFP genes were amplified using the primers
with BamHI and EcoRI restriction sites (Supplementary
Table S1, primer sets 1 and 2), and amplified fragments
were digested with the corresponding restriction enzymes.
Digested fragments were resolved in agarose gels and pu-
rified with the QIAquick Gel Extraction Kit (Qiagen), ac-
cording to the manufacturer’s instructions. CH1, CH2 and
CH3 genes were purchased in the form of gBlock (IDT).
The corresponding fragments were inserted in miRVec ex-
pression plasmid (restricted with the same enzymes) by liga-
tion with T4 ligase (Roche), according to the manufacturer’s
instructions. All constructs were tested by Sanger DNA se-
quencing at Beckman Coulter Genomics. HEK 293T was
transfected with CalPhos (Clontech) following the manu-
facturer’s instructions.
Similarly, PH20 and BWT genes were amplified and
flanked with AgeI and NotI restriction sites with corre-
sponding primers (Supplementary Table S1, primer sets 3
and 4). The amplicons were digested with AgeI and NotI en-
zymes, and the subsequent digested fragments were resolved
by agarose electrophoresis and purified with Monarch
DNA Gel Extraction Kit (New England Biolegends), ac-
cording to the manufacturer’s protocol. The correspond-
ing fragments were inserted in pGT4082 expression plas-
mid (restricted with the same enzymes) by ligation with T4
ligase (New England Biolegends), according to the manu-
facturer’s instructions.
Codon usage analysis
Codon usage frequencies were analyzed using the Sequence
Manipulation Suite (17). The relative codon usage was
obtained normalizing the codon usage of each codon
by every synonymous codon for each amino acid. The
Codon Adaptation Index (CAI) of each sequence and
the percentage of codons with G or C at the third base
position (GC3%) were calculated using the CAIcal server
from http://ppuigbo.me/programs/CAIcal/ (18). Homo
sapiens codon usage was extracted from the Codon Usage
Database available at http://www.kazusa.or.jp/codon/.
The human genes analysed were selected from the Tissue-
specific Gene Expression And Regulation database
at the Johns Hopkins University. Available trans-
gene sequences from the virus in clinical trials were
obtained from the corresponding patents: VCN-01
(EP2428229B1), NG-641 (WO2018041838A1), NG-350A
(WO2018220207A1), LoAd703 (WO2015155174A1),
Ad5-yCD/mutTKSR39rep-hIL12 (WO2007087462A2),
ONCOS-102 (WO2010072900) and CG0070
(WO2010072900). PCA, CAI and GC3% analysis were
represented using R v3.2.3 software.
Adenovirus generation and titration
Adwt and ICO15K backbones were previously generated
as described in (19,20). GFP, hyaluronidase and FAP-
targeting Bispecific T cell engager (FBiTE) transgenes were
introduced after fibre (L5 gene) under an IIIa splicing
acceptor (IIIaSA) (21) in the corresponding backbones
(19,20) to generate adenoviral genomes with transgenes in-
serted as late units (L6). Adenoviral genomes with GFPs in-
serted as an early gene were generated introducing the trans-
genes under the control of the constitutive cytomegalovirus
promoter (CMV) in the region between the E4 gene and
the right ITR. In all cases, transgenes were incorporated
following an adapted recombineering protocol based on
homologous recombination in bacteria (22,23). Recom-
bination fragments were obtained amplifying the trans-
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genes with primers with the corresponding homologous se-
quences (Supplementary Table S1, primer sets 5 to 8). BHU
transgene was purchased as a gBlock (IDT) flanked with
the corresponding homologous regions. FBiTE adenoviral
genome was previously generated (11). FBiTEHU trans-
gene was synthesized (ProteoGenix) and recombination
fragments were obtained by transgene amplification with
listed primer sequences (Supplementary Table S1, primer
set 13). Plasmids were transfected into HEK293 cells to
obtain the first round of viral particles. All viruses were
propagated in A549 cells and purified using cesium chlo-
ride double-gradients following standard techniques (24).
Adenoviral titres were calculated based on optical density
(using viral particles [vp]/ml) and on viral infectious units
(IFU/ml) as previously described (15).
Viral genomes quantification
Viral DNA was obtained from the supernatants of infected
cells using Norgen’s Blood DNA Isolation Mini Kit (NOR-
GEN BIOTEK CORP.). Adenoviral DNA content was
quantified by qPCR using LightCycler 480SYBER Green
I Master Mix (Roche Diagnostics), (Supplementary Table
S1, primer set 9). All qPCR reactions were done in a ViiA 7
Real-Time PCR System (Applied Biosystems).
cDNA synthesis and real-time qPCR
Total and viral RNA were obtained from infected cells using
RNeasy Mini Kit (Qiagen), 500 ng were reverse transcribed
using PrimeScript RT-PCR Kit (Takara), and the qRT-
PCR analysis was performed using LightCycler 480SYBER
Green I Master Mix (Roche Diagnostics; Supplementary
Table S1, primer sets 10 and 11). qRT-PCR results were nor-
malized to the beta-actin expression (Supplementary Table
S1, primer set 12). qPCR reactions were done in a ViiA 7
Real-Time PCR System (Applied Biosystems).
Western blot analyses
Total protein extracts were obtained using a lysis buffer
(50 mM Tris-HCl [pH 6.8], 2% SDS and 10% glycerol)
containing 1% Complete Mini Protease Inhibitor (Roche).
Cell lysates were boiled (10 min at 98ºC) and centrifuged
(5 min at 16 000 g) to eliminate insoluble cellular de-
bris. Protein concentration was determined by BCA Pro-
tein Assay Kit (ThermoFisher Scientific). Fifteen micro-
grams of protein were resolved by electrophoresis on a 10%
acrylamide gel and transferred to a nitrocellulose mem-
brane by standard methods. Membranes were incubated
with Anti-Adenovirus Type 5 Capsid antibody (1:1000; Ab-
cam) for hexon, penton, IIIa and V proteins detection and
with Adenovirus Fiber [4D2] antibody (1:200; GeneTex) for
fiber detection. Protein labeling was detected using HRP-
conjugated antibodies and visualized in the image reader
LAS4000 (Fujifilm). All protein expression data were nor-
malized to GAPDH protein expression (Supplementary
Figure S8).
For hyaluronidase quantification, supernatants from
HEK293 cells were collected 5 days after transfection with
pGT4082-hyaluronidase expressing plasmids. Equivolumes
of respective transfections (30 l) were resolved in a 12%
acrylamide gel together with a standard curve of commer-
cial purified recombinant His-tagged hPH20 (Acro Biosys-
tems, PH0-H5225). The gel was transferred to nitrocellu-
lose membrane, and overnight incubation with Anti-HisTag
antibody (1:4000, Dianova) was performed. Then, a sec-
ondary antibody anti-mouse-IgG HRP (1/2000, Dako) was
used to reveal and subsequent visualization of the western
blot in the Chemi-doc (BioRad).
Cytotoxicity
Cells were seeded in triplicate and infected with serial di-
lutions of each virus. At 4 h post infection, the virus-
containing medium was replaced with fresh medium. Cell
viability was measured at the indicated days post-infection
by a colorimetric assay, following the manufacturer’s in-
structions (MTT Ultrapure; USB).
Flow cytometry
Evaluation of fluorescence intensity by flow cytometry was
performed using Attune Acoustic Focusing Cytometer (Ap-
plied Biosystems) and analyzed using FlowJo 8.7 for Mac-
intosh.
Histological analysis
PANC-1 and MIA PaCa-2 tumours were fixed in a 4%
paraformaldehyde solution overnight and embedded in
paraffin. Standard Masson, and hematoxylin and eosin
staining were performed in 5 m sections. For hyaluronic
acid staining, permeabilization and blockade were done us-
ing PBS with 0.3% triton, 10% FBS and 1% BSA. HABP
(Sigma) at 5 g/ml was incubated overnight, and the HA
labelling was detected using Vectastain® ABC Kit (Vec-
tor Laboratories) and DAB (Vector Laboratories). Hema-
toxylin counterstaining was performed for 2 min at room
temperature (RT).
Hyaluronidase activity detection––turbidimetric assay
Supernatants from infected or transfected cells were mixed
with a HA (Sigma, St Louis, MO) solution in phosphate
buffer (pH 6.0) and incubated for 14 h at 37◦C. Standards
with known concentrations of hyaluronidase were incu-
bated in parallel to generate standard curves. Five volumes
of acid albumin (24 mM sodium acetate, 79 mM acetic acid,
0.1% bovine albumin [pH 3.75]) were added to all samples
and incubated for 10 min at RT. The hyaluronidase activity
was measured by light absorbance at 600 nm. Absorbance
values of supernatants were used to calculate hyaluronidase
activity by extrapolation to the standard curves.
FBiTE binding assay
A549 cells (5 × 106) were infected at MOI of 5 IFU/cell
with ICO15K-FBiTEHU or ICO15K-FBiTE. Seventy-two
hours post-infection, supernatants were collected and cen-
trifuged for 5 min at 1200 g to remove cellular debris. Super-
natants from uninfected cells were used as a mock control.
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The binding assay was performed with CD3+ Jurkat cells.
A total of 1 × 105 cells were incubated on ice for 1 h with 1
ml of the different supernatants. FBiTE binding was deter-
mined by flow cytometry using anti-FLAG M2-FITC mon-
oclonal antibody (Sigma Aldrich). Flow cytometry analysis
was performed on a Gallios cytometer (Beckman Coulter),
and data were processed with FlowJo v7.6.5 (Tree Star).
Antitumoural in vivo study
Subcutaneous tumours were generated in 6- to 7-week-old
male Athymic Nude Foxn1nu/nu mice (ENVIGO) by in-
jecting 2 × 106 MIA PaCa-2 or PANC-1 cells embedded
in Matrigel 1:1 (BD Biosciences) into each flank. Tumours
were measured at least twice weekly, and the tumoural vol-
umes calculated using the formula, V = D × d2 ×  ÷ 6
V. Mice were randomly assigned to either group for treat-
ment. Viruses (4 × 1010 vp/animal) were administered in-
travenously in physiological saline solution once tumours
achieved a median volume of 100 mm3. The experiment re-
mained blinded until the conclusion of the study. Animals
were euthanized 45–48 days after virus administration, and
tumours were collected and flash-freezed in liquid nitro-
gen. All animal procedures met the guidelines of European
Community Directive 86/609/EEC and were approved by
the ethical committee (CEEA-University of Barcelona) and
by the local authorities of the Generalitat de Catalunya.
Statistical analysis
Statistical analysis was performed on GraphPad Prism
v8.0.1 (GraphPad Software). Unless specified, statisti-
cal differences were evaluated using a two-tailed non-
parametric Mann–Whitney test. The level of significance
was set as P < 0.05.
The in vivo tumour growth statistical analysis was evalu-
ated using a linear mixed-effect model with the lme4 pack-
age in R v3.2.3. We associated a random-effects term with
the day of measurement (25). Statistical differences were
evaluated using a multiple comparison of means by Tukey’s
contrasts.
Web tool
ONATRY is a graphical user interface for analysing ade-
noviral transgene codon usage suitability. ONATRY rep-
resents transgenes in the context of viral genes, according
to their GC content and codon usage via principal com-
ponent analysis (PCA). It is implemented in R (version
3.6.3) and encapsulated in a Shiny application (https://shiny.
rstudio.com/). Users can access the tool via a web interface
(https://toolsr.fcrb.es/sample-apps/ONATRY/).
Our Shiny application pipeline provides two different
ways to input data for analysis. First, a file in fasta format
can be uploaded (through a ‘Choose FASTA file’ button).
Second, there is the possibility to paste sequences in fasta
format (via ‘paste FASTA’). ONATRY provides two visual-
ization tools: a density plot and a PCA representation for
exploratory analysis. The current implementation depends
on the following R packages: shiny, coRdon, dplyr, rgl and
progress.
RESULTS
Transgene codon usage impacts oncolytic adenoviral replica-
tion
Adenoviral genes display a fine-tuned codon usage, in which
highly abundant late structural proteins present codons fre-
quently used in the human host (optimal codons) in com-
parison to early regulatory proteins. However, not all struc-
tural proteins have optimal codon usage. Unlike the rest, the
adenoviral fibre displays a suboptimal codon usage, which
is necessary for codon balance and efficient viral replication
(15). Notably, analysis of the codon usage of transgenes ex-
pressed in OAds currently in clinical trials shows that most
transgenes also use suboptimal codons, as compared to the
overall codon usage in human genes (i.e. they have a codon
adaptation index [CAI] (26), a measure of directional syn-
onymous codon usage bias, lower than the average human
gene, Supplementary Figure S1A). This would contradict
the general paradigm that recommends using optimal host
codons in transgenes to maximize gene expression, and sug-
gest that this strategy could have a negative impact for ther-
apeutic OAd fitness.
To investigate the impact of the transgene codon usage
on the oncolytic viral fitness, we selected two reporter genes:
the enhanced green fluorescent protein (EGFP), a broadly
used GFP codon optimized to maximize its translation in
human cells, and the low codon-optimized GFP (LGFP),
which mimics the CAI of the transgenes expressed by the
OAds in clinical trials (Supplementary Figure S1B). Both
transgenes encode the same GFP amino acid sequence, but
with different codon usage (Figure 1A and Supplementary
Data S1). EGFP uses mainly codons with G or C at the
third base position (human optimal codons) while LGFP
uses more frequently codons with A or T at the third base
position (human non-optimal codons). The PCA of the rel-
ative codon usage of both EGFP and LGFP in relation to
the adenoviral genes shows that EGFP gene clusters in the
vicinity of the late structural and replication-related genes
in the first principal component (PC1), while LGFP gene
clusters with the early regulatory viral genes. (Figure 1B).
PC1 discriminates viral genes according to their relative use
of codons with G or C at the third base position (GC3). Pos-
itive PC1 values correlate with genes with low GC3 content
(and high AT3), while negative PC1 values correlate with
genes with high GC3 content (and low AT3). It has been
recently reported that GC3 codons are associated with hu-
man mRNA stability and with higher translation efficiency,
thereby increasing protein production (27).
To investigate the impact of codon usage in transgene ex-
pression, EGFP and LGFP were armed as late genes un-
der the control of the major late promoter (MLP) in the
wild-type adenovirus 5 (Adwt) genome, generating Adwt-
EGFP late and Adwt-LGFP late, respectively (Figure 1C).
No differences were found in the intracellular viral DNA
replication at first round of infection when infecting cells at
equal viral dosage (Figure 1D), while live-cell fluorescence
imaging of Awt-EGFP late and Adwt LGFP late revealed
that EGFP transgene expression was two orders of magni-
tude higher in relation to LGFP, as expected considering
its higher GC3 content (i.e. its optimal codon usage; Fig-
































































































































































































































































































 p = 0.7168
Adwt-EGFP_late       Adwt-LGFP_late        Adwt-GFPCH_late
Figure 1. Viral fitness is affected by late transgenes in a codon-dependent manner. (A) Schematic model of GFP transgenes: the enhanced green fluorescent
protein (EGFP, 96.7% of GC3 content) and the low codon-optimized GFP (LGFP, 44.8% of GC3 content). (B) Transgene codon usage evaluation by PCA:
loadings in the left panel show codons coloured according to the third nucleotide composition and scores in the right panel show the distribution of all
viral genes as well as EGFP and LGFP transgenes in the first two principal components (PC1 and PC2). Early adenovirus regulatory genes are represented
in light grey with an increased usage of AT3 codons (orange and red spheres). Late structural and replication genes are represented in dark grey, with
an increased usage of GC3 codons (grey and blue spheres). (C) Schematic representation of the whole adenoviral genome armed with EGFP or LGFP
transgenes under the MLP control. (D) Intracellular viral genomes at 4, 8, 12 and 36 hpi in A549 cells infected with 10 IFU of Adwt-EGFP late or
Adwt-LGFP late. Each dot represents an independent experimental replicate. (E) Fluorescence expression time course assay in A549 cells infected with
Adwt-EGFP late or Adwt-LGFP late at 5 IFU and analysed by IncuCyte (Essen Bioscience) live cell motorization during a period of 100 h. Data are
represented as the mean ± SEM of five independent experimental replicates. (F) Relative viral hexon and fibre mRNA content analysed by RT-qPCR at
36 hpi. Data are represented as the mean ± SEM; each dot corresponds to an independent experimental replicate. (G) Adenoviral late structural protein
expression analysis by WB at 36 hpi. Left and central panels show representative WB. The right panel shows WB quantification. Data are represented as
the mean ± SEM; each dot corresponds to an independent experimental replicate. (H) Quantification of the relative extracellular viral particles released to
the supernatants of A549 cells infected with 10 IFU of Adwt-EGFP late or Adwt-LGFP late at 36 hpi. Data are represented as the mean ± SEM; each dot
corresponds to an independent experimental replicate. (I) Proliferation assay of A549 cells infected with 5 IFU of Adwt-EGFP late, Adwt-LGFP late or
Adwt, analysed by IncuCyte live cell motorization during a period of 100 h. Data are represented as the mean ± SEM of four experimental replicates. (J)
Fluorescence analysis by flow cytometry at 48 hpi of A549 cells infected with 0.5 IFU of Adwt-EGFP late, Adwt-LGFP late or Adwt-GFPCH late. (K)
Relative extracellular viral particle release analysed by qPCR at 48 hpi. Data are represented as the mean ± SEM; each dot corresponds to an independent
experimental replicate.*P < 0.05 (two-tailed Mann–Whitney test); n.s., non-significant differences.
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ure 1E). Next, we assessed whether the transgene codon
usage had any effect on viral gene expression. Analysis of
the mRNA levels of the late-phase structural hexon gene,
a gene with a high percentage of GC3 codons, showed a
50% decrease in the mRNA content in cells infected with
Adwt-EGFP late in comparison with the ones infected with
Adwt-LGFP late. Interestingly, no differences in mRNA
levels were found in the structural fibre gene, the only late
structural gene with low GC3 content (Figure 1F). Western
blot analysis of late-phase hexon, penton, IIIa, V and fibre
proteins further showed that Adwt-EGFP late infected cul-
tures displayed lower expression of structural proteins with
high GC3 content, while fiber protein levels were similar
between viruses (Figure 1G). As a result of the impaired
expression of many late-phase proteins, Adwt-EGFP late
infected cultures showed six times less viral release than
the Adwt-LGFP late infected ones (Figure 1H). This dif-
ference in viral replication resulted in the impairment of
Adwt-EGFP late virus to control A549 cell proliferation
(Figure 1I). The reported differences with Adwt-EGFP late
and Adwt-LGFP late were not observed in parallel studies
conducted with transgenes inserted as early genes Adwt-
EGFP early and Adwt-LGFP early (Supplementary Fig-
ure S2). These results are in line with the concept of an in-
tergenic competition for cellular resources in transgenes en-
gineered to be expressed in the late phase of viral infection
but not during the early phase, when the host resources are
not yet monopolized by the virus. Altogether, these obser-
vations point out that, at the late phase of infection, trans-
gene codon usage would not only have cis effects on its own
expression but also trans effects on other viral proteins ex-
pressed.
For an effective therapeutic output, it is necessary to
properly balance the viral lytic activity and therapeutic
transgene expression. Therefore, we next evaluated whether
tuning transgene codon usage could allow a better trans-
gene expression without compromising viral replication.
We designed three new chimeric transgenes encoding GFP
(CH1, CH2 and CH3) by combining EGFP and LGFP se-
quences (Supplementary Figure S3A and B) to achieve in-
termediate codon usage optimization (Supplementary Fig-
ure S3C–F). GFP expression analysis upon transfection ev-
idenced that the levels of fluorescence of the different trans-
genes were highly dependent on their GC3 content (Supple-
mentary Figure S3F–D). CH1 transgene was selected and
armed under the MLP, generating Adwt-GFPCH late. Im-
portantly, Adwt-GFPCH late infected cultures presented
higher transgene expression capacity than cell cultures
infected with Adwt-LGFP late (Figure 1J) without im-
pairing viral fitness (Figure 1K). In this way, our results
suggest that oncolytic activity and late transgene expres-
sion can be optimized through the balancing of codon
usage.
Sustained therapeutic transgene expression depends on viral
fitness
To assess the importance of balancing the lytic activity
of the virus and the transgene expression in a therapeutic
context, we evaluated the impact of transgene codon us-
age in the design of oncolytic viruses. We selected two ver-
sions of the bee (Apis mellifera) hyaluronidase, with differ-
ent codon usages, as therapeutic transgenes (Supplemen-
tary Data S2). Previous oncolytic virus armed with the hu-
man hyaluronidase (PH20 gene expressed by the VCN-01
virus) showed that the expression of this enzyme allows tu-
mour microenvironment remodeling, making tumour cells
more accessible to antitumour treatments (6). Since bee
hyaluronidase presents higher enzymatic activity than its
human orthologue (Supplementary Figure S4), we rea-
soned that arming oncolytic viruses with bee hyaluronidase
could enhance their antitumour activity. We selected a hu-
manized version of the bee hyaluronidase (BHU), modified
following standard codon humanization algorithms (per-
formed by Genscript) (Supplementary Figure S5) display-
ing high GC3 content (Figure 2A), and the wild-type bee
hyaluronidase (BWT) with a suboptimal codon usage for
its expression in human cells (Supplementary Figure S5)
and a GC3 content similar to that of the CH1 gene (Fig-
ure 2A). We used the viral platform ICO15K (the same one
of the VCN-01 virus, currently in clinical trials) to express
the Apis mellifera hyaluronidase transgenes with different
codon usages (Figure 2B). ICO15K is a E1-24 engineered
adenovirus with four E2F and one sp-1 binding sites in the
E1A promoter and the RGDK motif replacing the KKTK
glycosaminoglycan binding domain in the fibre shaft
(6,19).
As expected, the virus expressing the human optimized
bee hyaluronidase, ICO15K-BHU, showed a significant im-
pairment of viral fitness, similar to the one of the Adwt-
EGFP late virus (Figure 2C and Supplementary Figure
S6A). Viral replication impairment was further evidenced
after several rounds of infection (Figure 2D). Indeed, af-
ter five rounds of consecutive infections, the ICO15K-BHU
virus became extinct (Figure 2D and E). Consequently,
BHU transgene hyaluronidase activity was not detected at
passage 5, despite displaying the highest enzymatic activ-
ity at passage 0 (Figure 2F). Cytotoxicity assays carried out
in pancreatic ductal adenocarcinoma (PDAC) cell models
PANC-1 (Figure 2G), MIA PaCa-2 and NP18 (Supplemen-
tary Figure S6B and C) evidenced a significant decrease
in the oncolytic capacity of ICO15K-BHU compared to
ICO15K-BWT, in concordance with its impaired viral repli-
cation.
These effects were also confirmed when analysing an on-
colytic adenovirus engineered to express another therapeu-
tically relevant transgene. The FAP-targeting Bispecific T
cell engager (FBiTE) gene has been engineered into the on-
colytic adenovirus ICO15K to improve the antitumoral ef-
fects by retargeting T cells to cancer-associated fibroblasts
(11). To analyse the impact of this transgene codon us-
age on viral replication, transgene expression and cytotoxic
effects, we compared the oncolytic adenovirus ICO15K-
FBiTE and a new virus armed with a codon-optimized
transgene ICO15K-FBiTEHU (Supplementary Figure S7A
and B). Again, we observed that the virus expressing the op-
timized version of the transgene showed impairment in vi-
ral replication, whereas expression of the transgene was re-
markably higher 72 h post infection (Supplementary Figure
S7C and D). Consequently, ICO15K-FBiTEHU cytotoxic-
ity was reduced when compared to ICO15K-FBiTE (Sup-
plementary Figure S7D).






























































































































































































Figure 2. Transgene optimization to human codon usage negatively affects viral replication and oncolysis. (A) principal component analysis of the relative
codon usage per amino acid of bee hyaluronidase transgenes: the left panel shows the loadings, codons characterized according to the third nucleotide
composition, the right panel shows the hyaluronidase transgenes in relation to adenoviral genes. (B) Schematic representation of ICO15K-BHU and
ICO15K-BWT virus, armed with codon humanized bee hyaluronidase (BHU) and codon wild-type bee hyaluronidase (BWT), respectively. (C) qPCR
relative quantitation of the extracellular viral particles released to the supernatants of PANC-1 cells infected with 5 IFU of VCN-01, ICO15K-BHU or
ICO15K-BWT at 72 hpi,. The dashed line represents VCN-01 values. Data are represented as the mean ± SEM; each dot corresponds to an independent
experimental replicate; **P < 0.01 (two-tailed Mann–Whitney test). (D) qPCR relative quantification of viral release in the supernatants of PANC-1
cells infected with ICO15K-BHU, ICO15K-BWT or ICO15K-BAd at several rounds of infection. The dashed line represents VCN-01 values. Data are
represented as mean ± SEM of four independent experiments. Differences between slopes were analysed using F-test for nonlinear models; ***P < 0.001. (E)
Hexon protein analysis by Western Blot at passage 5. Upper panel: representative WB. Lower panel: WB quantification of four independent replicates. The
dashed line represents VCN-01 values. (F) Turbidimetric quantification of hyaluronidase activity in the supernatants of PANC-1 cells infected with ICO15K-
BHU and ICO15K-BWT at passages p0 and p5. (G) In vitro oncolytic activity assay in PANC-1 cells. Cells were infected with a dose range of ICO15K-BHU
and ICO15K-BWT and their viability was measured 7 days PI by MTT assay. Viability curves are represented in the left panel as mean ± SEM of at least
four independent experiments. The right panel represents IC50 values as a box plot of four independent experiments. *P < 0.05 (two-tailed Mann–Whitney
test).
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Collectively, our results show that arming oncolytic aden-
oviruses with canonically humanized transgenes negatively
impacts viral replication. However, the therapeutic activity
of the virus can be rescued through a codon optimization
that takes into account the effect of the transgene on virus
replication.
Preserving viral lytic activity is key to maximize antitumoural
efficacy
To investigate how the interplay between transgene codon
optimization and viral lytic capacity impacts therapeutic
efficacy, we treated athymic mice bearing subcutaneous
PANC-1 and MIA PaCa-2 tumours with a collection of
OAds armed with different hyaluronidases. Both pancreatic
cell lines generate tumours with a high density of stroma,
mimicking pancreatic tumours. In these conditions, viral
spread is impaired and the antitumoural activity of OAds is
limited. Therefore, arming OAds with potent hyaluronidase
transgenes should boost the therapeutic activity of these
viruses. However, we observed that the virus expressing
the human optimized bee hyaluronidase, ICO15K-BHU,
was the least efficient in reducing tumour growth, size and
weight (Figure 3A–C and Supplementary Figure S8A–C).
Thus, despite displaying the highest hyaluronidase activity,
which led to a notable decrease of hyaluronic acid (Fig-
ure 3D and Supplementary Figure S8D), tumours treated
with this virus maintained high cellularity (Figure 3E and
Supplementary Figure S8E) demonstrating that prioritiz-
ing high transgene activity is insufficient for controlling
tumour progression if the viral lytic activity is impaired.
This is consistent with the results from our previous in
vitro analyses (Figure 2). On the contrary, treatment with
the virus expressing the bee hyaluronidase gene with sub-
optimal codon usage, ICO15K-BWT, resulted in the highest
antitumour activity (Figure 3A-C and Supplementary Fig-
ure S8A–C). When comparing the therapeutic activity of
ICO15K-BWT with the VCN-01 virus, which expresses the
human hyaluronidase and is currently in clinical trials, the
virus with the bee hyaluronidase showed increased antitu-
mour activity, both by efficiently remodelling the tumoural
microenvironment (Figure 3D–E) and by controlling tu-
moural growth (Figure 3A–C). In tumours derived from a
cell line with reduced viral sensitivity (i.e. MIA PaCa-2 and
Supplementary Figure S6B), ICO15K-BWT treatment con-
trolled tumour growth (similarly to VCN-01) (Supplemen-
tary Figure S8A–C) and enhanced tumoural microenviron-
ment remodelling (Supplementary Figure S8D), although
it was not capable of reducing cellularity in the remaining
tumour mass (Supplementary Figure S8E). The fact that
all viruses expressing Apis Mellifera hyaluronidase showed
a significant decrease of hyaluronic acid, when compared
to the VCN-01 virus expressing the human hyaluronidase
(Figure 3D and Supplementary Figure S8D) is in line
with our observations that bee hyaluronidase has a supe-
rior enzymatic activity (Supplementary Figure S3). Alto-
gether our results reveal that preserving viral lytic activ-
ity is key to maximize the therapeutic output of the virus
and highlight the importance of adequately balance vi-
ral fitness and transgene expression to optimize treatment
efficacy.
DISCUSSION
Oncolytic virotherapy depends on the viral capacity to suc-
cessfully replicate, lyse the tumour cell and generate new vi-
ral particles by taking advantage of cellular resources. Arm-
ing oncolytic viruses with therapeutic transgenes is required
to enhance the antitumour efficacy of viral therapies. Sur-
prisingly, our analysis shows that the therapeutic genes that
have been armed in OAds currently in clinical trials have a
codon usage that is not optimized to maximize their expres-
sion in human cells. Considering that codon optimization is
a commonly used strategy to maximize gene expression, we
speculated that the bias towards non-optimized transgenes
in armed OAds reaching the clinic was not random but re-
sponse to a biological mechanism not yet known. With the
aim to understand it, we systematically studied the impact
of the codon usage of therapeutic transgenes in OAd anti-
tumour activity. Using both reporter genes and transgenes
of therapeutic interest, we found that their codon usage
severely impacts viral replication and that viral replication
impairment is directly correlated to the expression of the
transgene. The viral–transgene competition diminishes vi-
ral replication over time thereby extinguishing the virus in as
few as five replication cycles, and consequently abrogating
therapeutic transgene expression. We found that preserving
viral lytic activity over transgene expression is the key ele-
ment to maximize the antitumour efficacy of the OAds.
Interestingly, we found that the viral–transgene competi-
tion is less important when expressing the transgenes during
the early stages of viral replication (Supplementary Figure
S2). This would be explained because the adenoviral early
regulatory genes have an AT3-biased codon usage that may
prevent the competition with GC3-rich optimized trans-
genes. Moreover, we speculate that differences in competi-
tion could be due to the ability of the cell to adapt to dif-
ferent translational demands in the early stages of infection,
while during the late phases of the viral replication cycle, the
cellular machinery is barely able to satisfy viral demand. In
fact, we have recently shown that during the late phase of in-
fection, cellular translational machinery is extensively and
exclusively exploited by the virus, leading to a fine-tuned
balance between the supply and demand of a limited pool
of cellular resources (15). In the same line, the data pre-
sented in our work suggest that interfering with this fine-
tuned translational equilibrium by expressing therapeutic
transgenes could generate a translational imbalance with a
dramatic effect on the therapeutic activity of OAds. Even
if this could suggest that the expression of transgenes in
the early phases of infection could be preferable, this strat-
egy is not always possible. Transgenes encoding toxic pro-
teins can impact viral replication or affect viral DNA syn-
thesis (7,28). Moreover, if the transgene length is close to
the viral encapsidation limit, the usage of exogenous pro-
moters, required for early expression, will further increase
the length of the construct, and further hinder viral assem-
bly. Arming therapeutic transgenes under the control of the
viral major late promoter can overcome or at least attenu-
ate these effects. However, in that case, the intergenic com-
petition of the virus and transgene observed in our work
has to be considered. To facilitate so, we have created the
web tool ONATRY (Oncolytic Adenovirus Transgene ana-
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Figure 3. Balanced virus and transgene expression lead to optimal therapeutic index response. (A) In vivo tumour growth assay in mice bearing subcuta-
neous PANC-1 tumours. Animals were intravenously treated with saline solution or 4 × 1010 vp/animal of either VCN-01, ICO15K-BHU or ICO15K-BWT
(n ≥ 6 animals/group). Follow-up of tumour volumes is represented as the mean of percentage of growth ± SEM. (B) Tumour weight at end point. (C)
Tumour volume at end point. (D) HA acid staining quantitation of deparaffinized tumour sections with HABP; scale bar: 100 m. Left panels: representa-
tive images of HA staining. Right panels: HA acid quantification representing the stained area in at least 5 fields from the tumour sections of at least three
different mice. (E) Tumour cellularity measured by Masson staining; scale bar: 100 m. Left panels: representative images of HA staining. Right panels:
HA acid quantification; *P < 0.05, **P < 0.01, ***P < 0.001, #P < 0.05, ##P < 0.01, $P < 0.05, $$P < 0.01, $$$P < 0.001. * represents statistical dif-
ferences in relation to the saline group; # represents statistical differences in relation to saline VCN-01 group; $ represents statistical differences in relation
to ICO15K-BHU group.
lYzer) that recapitulates two key analyses: transgene GC3
content analysis in human host context and codon usage
PCA in relation to adenoviral genes. The tool is available
at https://toolsr.fcrb.es/sample-apps/ONATRY/. We think
that the web tool we have developed could contribute to
identify incompatible transgene codon usages and thus help
to improve the viral design.
Traditionally, due to the limited packaging capacity of
viruses, transgene length has been considered as the main
constraint when designing armed OAds. Our data prompt
us to reconsider this strategy to design oncolytic viruses. In
particular, it highlights the need to consider the interplay
between adenoviral replication and transgene expression.
This would require a paradigm change in which OAds and
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Figure 4. Transgene codon usage drives therapeutic efficacy of armed oncolytic adenoviruses. Graphical representation of transgene codon usage impact
on viral fitness and oncolytic virotherapy therapeutic efficacy. This figure was created with Biorender.com.
transgenes are no longer seen as two separate elements that
can be simply combined, and instead consider them as a
holistic system. Thus, apparent poor transgene expression
as a result of a suboptimal codon usage can paradoxically
end up maximizing transgene expression over time, due to
a better viral replication combined with the inherent auto-
amplification of the treatment (Figure 4). Altogether, our
results suggest that oncolytic virus design should abandon
the traditional dogma of enhancing transgene expression as
much as possible and consider the efficacy of oncolytic ther-
apies as the combined effect of transgene expression and vi-
ral replication, where preserving viral lytic activity is key to
maximize antitumour efficacy.
In more general terms, our work points to the intrigu-
ing hypothesis that many oncolytic viruses may have never
reached clinical trials because the deleterious effect of the
expression of a codon-optimized transgene could have pre-
vented correct viral replication. We think that by fine-tuning
the codon usage of the therapeutic transgene, many of these
viruses could be rescued, directly impacting the efficacy and
availability of novel OAds for cancer treatment. In paral-
lel, our results suggest that codon optimization may be a
successful strategy in cases where transgene expression has
to be maximized and viral replication needs to be attenu-
ated. This could provide an attractive strategy for vaccine
development. In this scenario, optimization of the trans-
genic antigen would result in attenuation of viral replication
together with an increase in epitope expression boosting a
specific antigen immune response (29).
Altogether, our findings represent a new step forward in
the understanding of the interplay between transgenes and
therapeutic viruses and could guide new strategies fostering
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